BioPharmSignal logoBioPharmSignal

Biotech News

Allogene Therapeutics Announces Planned CEO Succession

Allogene Therapeutics (ALLO)Allogene Therapeutics2026-06-25 13:46 ESTCompany update

David Chang, M.D., Ph.D., to Transition from President and Chief Executive Officer Following Eight Years of Outstanding Leadership and Continue to Serve on the Board of Directors Zachary Roberts, M.D., Ph.D., EVP, Research & Development and Chief Medical Officer, Appointed President and Chief

Open original release

Related news

ALLOAllogene Therapeutics2026-06-25 13:46 EST

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

ALLOAllogene Therapeutics2026-06-25 13:46 EST

Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update

ALLOAllogene Therapeutics2026-06-25 13:46 EST

Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update

ALLOAllogene Therapeutics2026-06-25 13:46 EST

Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026

ALLOAllogene Therapeutics2026-06-25 13:46 EST

Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL

ALLOAllogene Therapeutics2026-06-25 13:46 EST

Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock

ALLOAllogene Therapeutics2026-06-25 13:46 EST

Allogene Therapeutics Announces Pricing of Public Offering of Common Stock

ALLOAllogene Therapeutics2026-06-25 13:46 EST

Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases

ALLOAllogene Therapeutics2026-06-25 13:46 EST

Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock

ALLOAllogene Therapeutics2026-06-25 13:46 EST

Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update

View all latest news

Allogene Therapeutics

Allogene Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

ALLOAllogene Therapeutics2026-06-26 08:45 EST

Allogene Therapeutics Announces Planned CEO Succession

ALLOAllogene Therapeutics2026-06-26 08:45 EST

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

ALLOAllogene Therapeutics2026-06-26 08:45 EST

Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update

ALLOAllogene Therapeutics2026-06-26 08:45 EST

Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update

ALLOAllogene Therapeutics2026-06-26 08:45 EST

Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biotechnology
Location
United States